CN103357015A - Local preparation for removing verruca and nail diseases and taking care of nails - Google Patents
Local preparation for removing verruca and nail diseases and taking care of nails Download PDFInfo
- Publication number
- CN103357015A CN103357015A CN2013102038263A CN201310203826A CN103357015A CN 103357015 A CN103357015 A CN 103357015A CN 2013102038263 A CN2013102038263 A CN 2013102038263A CN 201310203826 A CN201310203826 A CN 201310203826A CN 103357015 A CN103357015 A CN 103357015A
- Authority
- CN
- China
- Prior art keywords
- acid
- methyl
- fluoro
- topical products
- chloro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to an anhydrous product for a local part, and the product is used for removing verruca and nail diseases and taking care of nails. The product comprises one or more active components, one or more of lactic acid, malic acid, tartaric acid, nitric acid, and C1-C4-alkyl ester of hendecanoic acid or undecylenic acid, serving as a carrier, and biocompatible auxiliary agents which are optional according to requirements. The invention also relates to a method for preparing the product and an application thereof.
Description
The application is, and to be JIUYUE in 2005 29 days, application people the applying date be Bioequal AG, denomination of invention dividing an application for the Chinese patent application 200510105663.0 of " wart, disease of nail, and the local prescription used of fingernail maintenance ".
Technical field
The present invention is relevant a kind of anhydrous topical products, be used for the treatment of the maintenance of wart, disease of nail and fingernail, it comprises one or more active ingredients, as the C of one or more lactic acid, malic acid, tartaric acid, citric acid, hendecanoic acid or the 9-undecylenic acid of supporting agent
1-C
4-Arrcostab is with compatible adjuvant on the physiology that can optionally select.
The present invention is relevant a kind of method and application thereof for preparing these composites also.
Background technology
Wart (Verruca) is via virus, particularly papilloma polyoma vacuolation virus (Papovaviruses) causes, mostly be greatly at the optimum hyperplasia material that is called skin mamillary tissue under the keratic coagulation horn shape skin, be not easy to infiltrate.Have at least 50 kinds of different skin hyperplasia materials to be classified as wart, and it is caused by surpassing 100 kinds of Verrucosiss poison institutes, that is papillomavirus.Wherein be divided into especially the wire wart, elongated hyperplasia material appears at face, cervical region or eye face.Plane wart appears at face, the back of the hand, cervical region or chest.These warts may spread because scratching or shaving.So-called bar-shaped wart is still arranged in addition, and the extremely similar Herba Astragali Sinici of its profile can appear at head or cervical region, or a kind of periungual wart that appears at finger and hand is arranged, and also often appears at around the fingernail.In addition, more the wart of puzzlement and trouble appears at sole, is called the thorn-like wart, and utmost point refractory is treated.The topical therapeutic of wart, disease of nail and fingernail maintenance be free from side effects and treatment cost low.Eliminating wart and part are how to make capacity active component and adjuvant to pass through horny layer or the fingernail of wart with the subject matter of the application of composite in fingernail treatment and fingernail maintenance, infiltrate in the deep tissue that needs treatment, to get rid of subcuticular pathogen, for example: virus and fungal infection.Adopt conventional method can treat existing pathogen, and can eliminate its symptom by direct topical therapeutic.After stopping treatment, its symptom may recur but in most cases.Known some natural method that adopts is treated wart, but can't really guarantee successfully, because skin and cuticular infiltration are still problem.
Existing people proposes the method that direct local application active component improves therapeutic outcome, wherein active component is to use with so-called supporting agent, that is this material is except the dissolubility that improves active component, still to having good permeability by horny layer and fingernail, and have the ability to transport active component and pass through nail tissue.For example: among the EP-A-0 503 988 in the medicine of illustrated treatment mycosis ungualis except antifungal active component and aqueous medium (its at least part dissolve antimycotic agent), still comprise at least a hydroaropic substance that promotes antimycotic agent infiltration fingernail.Except many kinds of chemical compounds, also address with ethyl lactate as the material that promotes infiltration.This composite that is illustrated in EP-A-0 503 988 is because only can part lytic activity composition, the active component that therefore is only applicable to limit the quantity of.In addition, with regard to the viewpoint of water content in the composite, when using hydrolyzable chemical compound (as: ethyl lactate) as the promotion permeate substance, can't prepare stable composite, because these chemical compounds can decompose because of hydrolysis between the storage life.
There is no at present gratifying product and can be used for topical treatment of nail disease or local maintenance fingernail, wherein contained supporting agent should guarantee to transmit for a long time the aequum active component by horny layer and fingernail, enters lactulum unguis and fingernail base portion.
Summary of the invention
Therefore, the object of the invention is to solve and eliminate the relevant problem of wart, topical treatment of nail disease and local maintenance fingernail, but and provide a kind of medicine and face beautifying health keeping product of life-time service.
Therefore, the object of the invention is to solve and eliminate the relevant problem of wart, topical treatment of nail disease and local maintenance fingernail, but and provide a kind of medicine and face beautifying health keeping product of life-time service.
A kind of anhydrous topical products according to the present invention, it can treat wart, treatment disease of nail and maintenance fingernail, it is composed as follows:
A) one or more active ingredients,
B) as the C of one or more lactic acid, malic acid, tartaric acid, citric acid, hendecanoic acid or the 9-undecylenic acid of supporting agent
1-C
4Arrcostab, and
C) compatible adjuvant on the physiology that can optionally select.
In one embodiment, described topical products is characterized in that its ethyl ester that comprises lactic acid, malic acid, tartaric acid, citric acid, hendecanoic acid or 9-undecylenic acid is as supporting agent.
In another embodiment, described topical products is characterized in that, wherein comprises the isopropyl esters of lactic acid, malic acid, tartaric acid, citric acid, hendecanoic acid or 9-undecylenic acid as described supporting agent.
In one embodiment, described topical products is characterized in that it comprises ethyl lactate as described supporting agent.
The particular importance product of eliminating wart is the preparation that comprises thuyol.
In one embodiment, described topical products is characterized in that, it comprises one or more and is selected from following each thing and forms material among the group as described active component: synthetic or natural antimycotic agent, antibiotic, antibacterial, corticosteroid and nourishing and anabolic substance.
In another embodiment; described topical products is characterized in that; it comprises one or more and is selected from following each thing and forms described antifungal active ingredient among the group: (±)-cis-2; 6-dimethyl-4-[2-methyl-3-(p-tertiary pentyl-phenyl) propyl group] morpholine (An Mofen (Amorolfin)); amphotericin (Amphotericin); 6-cyclohexyl-1-hydroxy-4-methyl-2 (1H)-pyridone (cyclopirox (Ciclopirox)); two-phenyl-(2-chlorphenyl)-1-imidazole radicals methane (clotrimazole (Clotrimazol)); l-[2-(2; the 4-Dichlorobenzene base)-2-(4-chlorophenylmethyl oxygen)-ethyl]-imidazoles (econazole (Econazol)); 2; 4-two fluoro-α; α-two (1H-l; 2; 4-triazole-l-ylmethyl) benzylated polyol (fluconazol (Fluconazol)); 5-flurocytosine (Flucytosin (Flucytosin)); 7-chloro-trimethoxy-methylspiro-[benzofuran-cyclohexene]-diketone (griseofulvin (Griseofulvin)); l-[2; 4-two chloro-β-(2; 6-dichloro-benzenes methyl oxygen)-phenethyl]-imidazoles (isoconazole (Isoconazol)); (±)-l-sec-butyl-4-{4-[4-(4-{[(2R*; 4S*)-2-(2; the 4-Dichlorobenzene base)-2-(1; 2; 4-triazol-1-yl methyl)-1; 3-dioxolanes-4-yl] methoxyl group } phenyl)-the 1-piperazinyl] phenyl }-4; 5-dihydro-1; 2; 4-triazole-5-ketone (itraconazole (Itraconazol)); ([2-(2 for (±) cis-l-acetyl group-4-{4-; the 4-Dichlorobenzene base)-2-(1H-imidazoles-l-ylmethyl)-l; 3-dioxolanes-4-yl] methoxyl group) phenyl } piperazine (ketoconazole (Ketoconazol)); l-[2; 4-two chloro-β-(2; 4-dichloro-benzenes methyl oxygen)-phenethyl]-imidazoles (miconazole (Miconazol)); (E)-N-cinnamyl-N-methyl isophthalic acid-naphthyl methyl amine (naftifine (Naftifin)); nystatin (Nystatin); (E)-(6; 6-dimethyl-2-heptene-4-alkynyl)-N-methyl isophthalic acid-naphthyl methyl amine (terbinafine (Terbinafin)); 1-[2-{ (2-chloro-3-thienyl) methoxyl group }-2-(2; the 4-Dichlorobenzene base) ethyl]-1H-imidazoles (tioconazole (Tioconazol)); O-2-naphthyl-N-methyl-N-(3-tolyl)-thiocarbamate (tolnaftate (Tolnaftat)); α-(2; the 4-difluorophenyl)-5-fluoro-beta-methyl-α-(1H-1; 2,4-triazol-1-yl methyl)-4-pyrimidine ethanol (voriconazole (Voriconazol)).
In one embodiment, described topical products is characterized in that it comprises one or more and is selected from: described antibacterium or described antifungal active component in tea tree ethereal oil, Essential lavender oil, thuyol, Azadirachta Indica A. tree extract and the ABC oil.
In one embodiment; described topical products; it is characterized in that it comprises one or more and is selected from following each thing and forms described antibiotic activity composition among the group: alpha-amido-4-hydroxy benzenes heterocyclic group containing (amoxicillin (Amoxicillin)); D-(-)-alpha-amido benzyl penicillin (ampicillin (Ampicillin)); 3; 3-dimethyl-7-oxo-6-phenylacetyl amido-4-thia-1-azabicyclo-[3.2.0]-heptane-2-carboxylic acid (benzylpcnicillin); benzylpcnicillin-benzyl star; 3-chloro-7-D (the 2-phenylglycine is amino)-cephalo acid (cefaclor (Cefaclor)); 7 β-[D-2-amino-(4-hydroxyl-phenyl)-acetyl-amino]-3-methyl-cephalo acid (cefadroxil (Cefadroxil)); aminophenyl-acetylaminohydroxyphenylarsonic acid methyl-cephalo acid (cefalexin (Cefalexin)); D (-)-p-2-dichloro acetamino-1-(4-nitrobenzophenone)-1; ammediol (chloromycetin (Chloramphenicol); 1-cyclopropyl-6-fluoro-1; 4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinoline carboxylic acid (ciprofloxacin (Ciprofloxacin)); (Z)-(2R; 5R)-3-(2-hydroxy ethylene)-7-oxo-4-oxa--1-azabicyclo [3.2.0] heptane-2-carboxylic acid (clavulanic acid (Clavulanic acid)); 7-chloro-7-deoxidation-lincomycin (clindamycin (Clindamycin)); 6-deoxidation-5-hydroxyl tetracycline (doxycycline (Doxycyclin)); 1-ethyl-6-fluoro-1; 4-dihydro-4-oxo-7-(l-piperazinyl)-l; 8-naphthyridines-3-carboxylic acid (Yi Nuoshaxin (Enoxacin)); erythromycin; 3-(2-chloro-6-fluorophenyl)-5-methyl-4-isoxazolyl-penicillin (flucloxacillin (Flucloxacillin)); kanamycin (Kanamycin); lincomycin (Lincomycin); 7-dimethylamino-6-deoxidation-6-declomycin (minocycline (Minocyc-lin)); 6-(2-ethyoxyl-1-naphthoyl amido)-penicillin (nafcillin (Nafcilin)); l-ethyl-l; 4-dihydro-7-methyl-4-oxo-l; 8-naphthyridines-3-carboxylic acid (nalidixic acid (Nalidxic acid)); neomycin (Neomycin); l-ethyl-6-fluoro-l; 4-dihydro-4-oxo-7-(l-piperazinyl)-3-quinoline carboxylic acid (norfloxacin (Norfloxacin)); (±)-9-fluoro-2; 3-dihydro-3-methyl isophthalic acid 0-(4-methyl isophthalic acid-piperazinyl)-7-oxo-7H-pyrido [l; 2; 3-de] [l; 4] benzoxazine-6-carboxylic acid (ofloxacin (Ofloxacin)); 6-(5-methyl-3-phenyl-4-isoxazole carboxamide groups) penicillanic acid (toluene isoxazolyl penicillin (Oxacillin)); 6-phenoxy group acetyl-amino-penicillanic acid (phenoxymethyl penicillin) and 4-dimethyl amido-octahydro-penta hydroxy group-1,11-dioxo-6-methyl-naphthonaphthalene-2-urea (tetracycline).
In another embodiment, described topical products, it is characterized in that it comprises one or more and is selected from following each thing and forms described Antibacterial Constituents among the group: alkylbenzene methyl dimethoxy ammonium chloride (benzene is pricked chlorine ammonia), N-benzyl-N, N-dimethyl-2-{2-[p-(1,1,3, the 3-tetramethyl butyl)-phenoxy group]-ethyoxyl }-ethyl ammonium hydroxide (benzethonium chloride), cetyl trimethylammonium hydroxide (cetrimonium bromide (Cetrimonium bromid)), 1,1 '-hexa-methylene-two-[5-(rubigan)-biguanide] (hibitane (Chlorhexidin)), N
1, N
1-decamethylene-two-(4-amino methyl quinaldine hydroxide) (dequaline chloride (Dequalinium chlorid)), N-(4-chlorphenyl)-N '-(3, the 4-Dichlorobenzene base) urea (neko (Triclocarbane)), 5-chloro-2-(2,4-dichlorophenoxy) phenol (triclosan (Triclosan)).
In one embodiment; described topical products; it is characterized in that it comprises one or more and is selected from following each thing and forms described corticosteroid active component among the group: 9 α-chloro-16 Beta-methyl hydrogenation Bo Nisong (beclometasone (Beclomethason)); 9-fluoro-l1 β; 17; 21-trihydroxy-16 Beta-methyl-1; 4-pregnant diene-3; 20-diketone (betamethasone (Betamethason)); 21-chloro-9-fluoro-11 β; 17-dihydroxy-16 Beta-methyl-1; 4-pregnant diene-3; 20-diketone (Clobetasol (Clobetasol)); 17; 21-dihydroxy-pregnant-4-alkene-3; 11; 20-triketone (cortisone (Cortisone)); 11 β; 16 α; 17 α; 21-tetrahydroxy-1; 4-pregnant diene-3; 20-diketone-16; 17-acetone acetal (desonide (Desonid)); 9-fluoro-l1 β-17; pregnant steroid-the l of 21-trihydroxy-16 Alpha-Methyl; 4-diene-3; 20-diketone (dexamethasone (Dexamethason)); 9 α; 11 β-two chloro-, 6 α-fluoro-21-hydroxy-16 alpha-; 17 α-(isopropylidene dioxy)-pregnant steroid-1; 4-diene-3; 20-diketone (flucloronide (Flucloronid)); 6 α; 9 α-two fluoro-, 16 α; 17 α-isopropylidene dioxy-corticosterone (fluocinonide (Fluocinolonacetonid)); 6 α; 9 α-two fluoro-, 16 α; 17 α-isopropylidene dioxy-corticosterone-acetate (fluocinonide (Fluocinonid)); 6 α-fluoro-11 β; 21-dihydroxy-6 α; 17-isopropylidene dioxy-4-pregnene-3; 20-diketone (flurandrenolide (Fludroxycortid)); 3-(2-chloroethoxy)-9 α-fluoro-6-formoxyl-11 β; 21-dihydroxy-16 α; 17 α-isopropylidene dioxy pregnant-3; 5-diene-20-ketone (formocortal (Formocortal)); 21-chloro-9 α-fluoro-11 beta-hydroxies-16 α; 17 α-isopropylidene dioxy-4-pregnene-3; 20-diketone (breathing out western naphthalene moral (Halcinonid)); 17 Alpha-hydroxy corticosterones (hydrocortisone (Hydrocortison)); 11 β; 17; 21-trihydroxy-6 Alpha-Methyl-1; 4-pregnant diene-3; 20-diketone (medrat (Methylprednisolon)); 11 β; 17; 21-trihydroxy-pregnant-1; 4-diene-3; 20-diketone (meticortelone (Prednisolon)); 17 α; 21-dihydroxy-pregnant-1; 4-diene-3; 11; 20-triketone (prednisone (Prednison)); 9-fluoro-16 Alpha-hydroxy andrographolides (acetone Triamcinolone (Triamcinolon)); acetone Triamcinolone-16 α, 17 α-acetone solvate (triamcinolone acetonide (Triamcinolonacetonid)).
In one embodiment, described topical products is characterized in that it comprises nourishing and anabolic substance L-PROLINE.
In one embodiment, described topical products is characterized in that it comprises described L-PROLINE and one or more and is selected from aminoacid, vitamin and mineral and forms nourishing among the group and the combination of anabolic substance.
In another embodiment, described topical products is characterized in that it comprises described L-PROLINE and one or more are selected from: lysine, cysteine, gelatin, biotin, panthenol, pantothenylol and the nourishing of inorganic or organic calcium, magnesium or zinc compound and the combination of anabolic substance.
In one embodiment, described topical products is characterized in that it comprises one or more and is selected from following each thing and forms adjuvant among the group: terpenes or contain oil, alcohol, ketone, fatty acid ester, Polyethylene Glycol, surfactant, carbamide, antioxidant and the chelating agent of terpenes.
In another embodiment, described topical products is characterized in that it comprises one or more active ingredients of 0.01 to 20 % by weight, the C of the lactic acid of 1 to 99.99 % by weight, malic acid, tartaric acid, citric acid, hendecanoic acid or 9-undecylenic acid
1-C
4-Arrcostab is with 0 to 98.99 % by weight adjuvant.
In one embodiment, a kind of method for preparing described topical products is characterized in that evenly mixing the C of one or more lactic acid, malic acid, tartaric acid, citric acid, hendecanoic acid or 9-undecylenic acid
1-C
4Then-Arrcostab and one or more adjuvant that can optionally select stir and add one or more active ingredients to mixture, heating for dissolving optionally, and continue to be stirred to and form till the homogeneous solution.
In another embodiment, a kind of method for preparing described topical products is characterized in that can adding in the described solution compatible allotment adjuvant on other physiology, prepares described topical products.
The present invention also relates to described topical products for the preparation for the treatment of, prevention, post processing or supportive treatment wart, disease of nail and first week disease the application of medicine.
The invention further relates to the application of described topical products in the fingernail maintenance.
The present invention also further relates to described topical products in the application for the preparation of the medicine of the fungal infection of hoof, pawl and the hook for the treatment of house pet and domestic animal.
Therefore, the object of the invention is to solve and eliminate the relevant problem of wart, topical treatment of nail disease and local maintenance fingernail, but and provide a kind of medicine and face beautifying health keeping product of life-time service.
A kind of anhydrous topical products according to the present invention, it can treat wart, treatment disease of nail and maintenance fingernail, it is composed as follows:
A) one or more active ingredients,
B) as the C of one or more lactic acid, malic acid, tartaric acid, citric acid, hendecanoic acid or the 9-undecylenic acid of supporting agent
1-C
4Arrcostab, and
C) compatible adjuvant on the physiology that can optionally select.
The anhydrous topical products of the present invention can adopt all can treat synthesizing with natural materials as active component of wart, fingernail and first week disease basically.Also can use the nourishing that effectively to maintain fingernail and anabolic substance as active component.
The suitable active composition that product can comprise according to the present invention is antimycotic agent (comprising synthetic and the natural origin person), antibiotic, antibacterial, corticosteroid, nourishing and anabolic substance, and combination.The special example of these active component is:
Compatible salt on-antimycotic agent and its physiology; as; for example: (±)-cis-2; 6-dimethyl-4-[2-methyl-3-(p-tertiary pentyl-phenyl) propyl group] morpholine (An Mofen (Amorolfin)); amphotericin (Amphotericin); 6-cyclohexyl-1-hydroxy-4-methyl-2 (1H)-pyridone (cyclopirox (Ciclopirox)); two-phenyl-(2-chlorphenyl)-1-imidazole radicals methane (clotrimazole (Clotrimazol)); l-[2-(2; the 4-Dichlorobenzene base)-2-(4-chlorophenylmethyl oxygen)-ethyl]-imidazoles (econazole (Econazol)); 2; 4-two fluoro-α; α-two (1H-l; 2; 4-triazole-l-ylmethyl) benzylated polyol (fluconazol (Fluconazol)); 5-flurocytosine (Flucytosin (Flucytosin)); 7-chloro-trimethoxy-methylspiro-[benzofuran-cyclohexene]-diketone (griseofulvin (Griseofulvin)); l-[2; 4-two chloro-β-(2; 6-dichloro-benzenes methyl oxygen)-phenethyl]-imidazoles (isoconazole (Isoconazol)); (±)-l-sec-butyl-4-{4-[4-(4-{[(2R*; 4S*)-2-(2; the 4-Dichlorobenzene base)-2-(1; 2; 4-triazol-1-yl methyl)-1; 3-dioxolanes-4-yl] methoxyl group } phenyl)-the 1-piperazinyl] phenyl }-4; 5-dihydro-1; 2; 4-triazole-5-ketone (itraconazole (Itraconazol)); ([2-(2 for (±) cis-l-acetyl group-4-{4-; the 4-Dichlorobenzene base)-2-(1H-imidazoles-l-ylmethyl)-l; 3-dioxolanes-4-yl] methoxyl group) phenyl } piperazine (ketoconazole (Ketoconazol)); l-[2; 4-two chloro-β-(2; 4-dichloro-benzenes methyl oxygen)-phenethyl]-imidazoles (miconazole (Miconazol)); (E)-N-cinnamyl-N-methyl isophthalic acid-naphthyl methyl amine (naftifine (Naftifin)); nystatin (Nystatin); (E)-N-(6; 6-dimethyl-2-heptene-4-alkynyl)-N-methyl isophthalic acid-naphthyl methyl amine (terbinafine (Terbinafin)); 1[2-{ (2-chloro-3-thienyl) methoxyl group }-2-(2; the 4-Dichlorobenzene base) ethyl]-1H-imidazoles (tioconazole (Tioconazol)); O-2-naphthyl-N-methyl-N-(3-tolyl)-thiocarbamate (tolnaftate (Tolnaftat)); α-(2; the 4-difluorophenyl)-5-fluoro-beta-methyl-α-(1H-1; 2,4-triazol-1-yl methyl)-4-pyrimidine ethanol (voriconazole (Voriconazol)).
-natural antimycotic agent, as, for example: volatile oil and plant extract.
Compatible salt on-antibiotic and its physiology, as, for example: alpha-amido-4-hydroxy benzenes heterocyclic group containing (amoxicillin (Amoxicillin)), D-(-)-alpha-amido benzyl penicillin (ampicillin (Ampicillin)), 3,3-dimethyl-7-oxo-6-phenylacetyl amido-4-thia-1-azabicyclo-[3.2.0]-heptane-2-carboxylic acid (benzylpcnicillin (Benzylpenicillin)), benzylpcnicillin-benzyl star (Benzylpenicillin-benzathin), 3-chloro-7-D (the sweet amine propylhomoserin of 2-phenyl is amino)-cephalo acid (cefaclor (Cefaclor)), 7 β-[D-2-amino-(4-hydroxyl-phenyl)-acetylamino]-3-methyl-cephalo acid (cefadroxil (Cefadroxil)), aminophenyl-acetylaminohydroxyphenylarsonic acid methyl-cephalo acid (cefalexin (Cefalexin)), D (-)-p-2-dichloro acetamino-1-(4-nitrobenzophenone)-1, ammediol (chloromycetin (Chloramphenicol), 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinoline carboxylic acid (ciprofloxacin (Ciprofloxacin)), (Z)-(2R, 5R)-3-(2-hydroxy ethylene)-7-oxo-4-oxa--1-azabicyclo [3.2.0] heptane-2-carboxylic acid (clavulanic acid (Clavulanic acid)), 7-chloro-7-deoxidation-lincomycin (clindamycin (Clindamycin)), 6-deoxidation-5-hydroxyl tetracycline (doxycycline (Doxycyclin)), 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(l-piperazinyl)-l, 8-naphthyridines-3-carboxylic acid (Yi Nuoshaxin (Enoxacin)), erythromycin, 3-(2-chloro-6-fluorophenyl)-5-methyl-4-isoxazolyl-penicillin (flucloxacillin (Flucloxacillin)), kanamycin (Kanamycin), lincomycin (Lincomycin), 7-dimethylamino-6-deoxidation-6-declomycin (minocycline (Minocyclin)), 6-(2-ethyoxyl-1-naphthoyl amido)-penicillin (nafcillin (Nafcillin)), l-ethyl-l, 4-dihydro-7-methyl-4-oxo-l, 8-naphthyridines-3-carboxylic acid (nalidixic acid (Nalidixic acid)), neomycin (Neomycin), l-ethyl-6-fluoro-l, 4-dihydro-4-oxo-7-(l-piperazinyl)-3-quinoline carboxylic acid (norfloxacin (Norfloxacin)), (±)-9-fluoro-2,3-dihydro-3-methyl isophthalic acid 0-(4-methyl isophthalic acid-piperazinyl)-7-oxo-7H-pyrido [l, 2,3-de] [l, 4] benzoxazine-6-carboxylic acid (ofloxacin (Ofloxacin)), 6-(5-methyl-3-phenyl-4-isoxazole carboxamide groups) penicillanic acid (toluene isoxazolyl penicillin (Oxacillin)), 6-phenoxy group acetylaminohydroxyphenylarsonic acid penicillanic acid (phenoxymethyl penicillin), 4-dimethyl amido-octahydro-penta hydroxy group-1,11-dioxo-6-methyl-naphthonaphthalene-2-urea (tetracycline).
-antibacterial, as, for example: alkylbenzene methyl dimethoxy ammonium chloride (benzalkonium chloride (Benzalkonium chloride)), N-benzyl-N, N-dimethyl-2-{2-[p-(1,1,3, the 3-tetramethyl butyl)-phenoxy group]-ethyoxyl }-ethyl ammonium hydroxide (benzethonium chloride (benzethonium chloride)), cetyl trimethylammonium hydroxide (cetrimonium bromide (Cetrimonium bromid)), 1,1 '-hexa-methylene-two-[5-(rubigan)-biguanide] (hibitane (Chlorhexidin)), N
1, N
1-decamethylene-two-(4-amino methyl quinaldine hydroxide) (dequaline chloride (Dequalinium chlorid)), N-(4-chlorphenyl)-N '-(3, the 4-Dichlorobenzene base) urea (neko (Triclocarbane)), 5-chloro-2-(2,4-dichlorophenoxy) phenol (triclosan (Triclosan)).
Compatible salt on-corticosteroid and its physiology; as; for example: 9 α-chloro-16 Beta-methyl hydrogenation Bo Nisong (beclometasone (Beclomethason)); 9-fluoro-l1 β; 17; 21-trihydroxy-16 Beta-methyl-1; 4-pregnant diene-3; 20-diketone (betamethasone (Betamethason)); 21-chloro-9-fluoro-11 β; 17-dihydroxy-16 Beta-methyl-1; 4-pregnant diene-3; 20-diketone (Clobetasol (Clobetasol)); 17; 21-dihydroxy-pregnant-4-alkene-3; 11; 20-triketone (cortisone (Cortisone)); 11 β; 16 α; 17 α; 21-tetrahydroxy-1; 4-pregnant diene-3; 20-diketone-16; 17-acetone acetal (desonide (Desonid)); 9-fluoro-l1 β-17; pregnant steroid-the l of 21-trihydroxy-16 Alpha-Methyl; 4-diene-3; 20-diketone (dexamethasone (Dexamethason)); 9 α; 11 β-two chloro-, 6 α-fluoro-21-hydroxy-16 alpha-; 17 α-(isopropylidene dioxy)-pregnant steroid-1; 4-diene-3; 20-diketone (flucloronide (Flucloronid)); 6 α; 9 α-two fluoro-, 16 α; 17 α-isopropylidene dioxy-corticosterone (fluocinonide (Fluocinolonacetonid)); 6 α; 9 α-two fluoro-, 16 α; 17 α-isopropylidene dioxy-corticosterone-acetate (fluocinonide (Fluocinonind)); 6 α-fluoro-11 β; 21-dihydroxy-6 α; 17-isopropylidene dioxy-4-pregnene-3; 20-diketone (flurandrenolide (Fludroxycortid)); 3-(2-chloroethoxy)-9 α-fluoro-6-formoxyl-11 β; 21-dihydroxy-16 α; 17 α-isopropylidene dioxy pregnant-3; 5-diene-20-ketone (formocortal (Formocortal)); 21-chloro-9 α-fluoro-11 beta-hydroxies-16 α; 17 α-isopropylidene dioxy-4-pregnene-3; 20-diketone (breathing out western naphthalene moral (Halcinonid)); 17 Alpha-hydroxy corticosterones (hydrocortisone (Hydrocortison)); 11 β; 17; 21-trihydroxy-6 Alpha-Methyl-1; 4-pregnant diene-3; 20-diketone (medrat (Methylprednisolon)); 11 β; 17; 21-trihydroxy-pregnant-1; 4-diene-3; 20-diketone (meticortelone (Prednisolon)); 17 α; 21-dihydroxy-pregnant-1; 4-diene-3; 11; 20-triketone (prednisone (Prednison)); 9-fluoro-16 Alpha-hydroxy andrographolides (acetone Triamcinolone (Triamcinolon)); acetone Triamcinolone-16 α, 17 α-acetone solvate (triamcinolone acetonide (Triamcinolonacetonid)).
Nourish and anabolic substance, for example, pyrrolidine 2 carboxylic acid (L-PROLINE).Better antimycotic agent is two-phenyl-(2-chlorphenyl)-l-imidazole radicals methane (clotrimazole (Clotrimazol)) according to the present invention; 1-[2; 4-two chloro-β-(2; 6-dichloro-benzenes methyl oxygen)-phenethyl]-imidazoles (isoconazole (Isoconazol)); 2; 4-two fluoro-α; α-two (1H-l; 2; 4-triazole-l-ylmethyl) benzylated polyol (fluconazol (Fluconazol)); (±)-l-sec-butyl-4-{4-[4-(4-{[(2R*; 4S*)-2-(2; the 4-Dichlorobenzene base)-2-(l; 2; 4-triazol-1-yl methyl)-1; 3-dioxolanes-4-yl] methoxyl group } phenyl)-the 1-piperazinyl] phenyl }-4; 5-dihydro-l; 2; 4-triazole-5-ketone (Yi Diankang azoles (Itraconazol)); ([2-(2 for (±) cis-1-acetyl group-4-{4-; the 4-Dichlorobenzene base)-2-(1H-imidazoles-1-ylmethyl)-1; 3-dioxolanes-4-yl] methoxyl group) phenyl } piperazine (ketoconazole (Ketoconazol)); 1-[2; 4-two chloro-β-(2; 4-dichloro-benzenes methyl oxygen)-phenethyl]-imidazoles (miconazole (Miconazol)); (E)-N-(6; 6-dimethyl-2-heptene-4-alkynyl)-N-methyl isophthalic acid-naphthyl methyl amine (terbinafine (Terbinafin)); α-(2; the 4-difluorophenyl)-5-fluoro-beta-methyl-α-(1H-l; 2,4-triazole-l-ylmethyl)-4-pyrimidine ethanol (voriconazole (Voriconazol)).
Better antimycotic agent is two-phenyl-(2-chlorphenyl)-1-imidazole radicals methane (clotrimazole (Clotrimazol)) according to the present invention; 1-[2; 4-two chloro-β-(2; 6-dichloro-benzenes methyl oxygen)-phenethyl]-imidazoles (isoconazole (Isoconazol)); (±)-1-sec-butyl-4-{4-[4-(4-{[(2R*; 4S*)-2-(2; the 4-Dichlorobenzene base)-2-(l; 2; 4-triazole-l-ylmethyl)-1; 3-dioxolanes-4-yl] methoxyl group } phenyl)-the 1-piperazinyl] phenyl }-4; 5-dihydro-l; 2; 4-triazole-5-ketone (Yi Diankang azoles (Itraconazol)); ([2-(2 for (±) cis-l-acetyl group-4-{4-; the 4-Dichlorobenzene base)-and 2-(1H-imidazoles-l-ylmethyl)-DOX-4-yl] methoxyl group) phenyl } piperazine (ketoconazole (Ketoconazol)).
Better natural antimycotic agent is tea tree oil (Melaleuca alternifolia), Essential lavender oil (Lavandula officinalis chaix) and Azadirachta Indica A. tree extract (Azadirachta indica).These natural antimycotic agents can use as active component separately or be used in combination with other multiple these active component.Better active component is combined as Essential lavender oil, tea tree oil and Azadirachta Indica A. tree extract, and particularly thuyol is used for eliminating wart.Better antibacterial be as, for example: 1,1 '-hexa-methylene-two-[5-(p-chlorphenyl)-biguanide] (hibitane (Chlorhexidin)).
Better corticosteroid is 11 β; 16 α; 17 α; 21-tetrahydroxy-1; 4-pregnant diene-3; 20-diketone-16; 17-acetone acetal (desonide (Desonid)); 9 α; 11 β-two chloro-, 6 α-fluoro-21-hydroxy-16 alpha-; 17 α-(isopropylidene dioxy)-pregnant steroid-1; 4-diene-3; 20-diketone (fluorine how moral (Flucloronid)); 6 α; 9 α-two fluoro-, 16 α; 17 α-isopropylidene dioxy-corticosterone (fluocinonide (Fluocinolonacetonid)); 6 α; 9 α-two fluoro-, 16 α; 17 α-isopropylidene dioxy-corticosterone-acetate (fluocinonide (Fluocinonind)); 6 α-fluoro-11 β; 21-dihydroxy-6 α; 17-isopropylidene dioxy-4-pregnene-3; 20-diketone (flurandrenolide (Fludroxycortid)); 3-(2-chloroethoxy)-9 α-fluoro-6-formoxyl-11 β; 21-dihydroxy-16 α; 17 α-isopropylidene dioxy pregnant-3; 5-diene-20-ketone (formocortal (Formocortal)); 21-chloro-9 α-fluoro-11 beta-hydroxies-16 α; 17 α-isopropylidene dioxy-4-pregnene-3; 20-diketone (breathing out western naphthalene moral (Halcinonid)); hydrogen hydroxyl meticortelone-16 α, 17 α-acetone solvate (triamcinolone acetonide (Triamcinolonacetonid)).
The specific combination example of active ingredient is:
The combination of corticosteroid and antimycotic agent, antibiotic or antibacterial.Better for example being combined as: ([2-(2 for (±) cis-l-acetyl group-4-{4-; the 4-Dichlorobenzene base)-2-(1H-imidazoles-l-ylmethyl)-l; 3-dioxolanes-4-yl] methoxyl group) phenyl }-piperazine (ketoconazole (Ketoconazol)) and 11 β; 16 α; 17 α, 21-tetrahydroxy-Isosorbide-5-Nitrae-pregnant diene-3; 20-diketone-16, the combination of 17-acetone acetal (desonide (Desonid)).
The combination of synthetic property antimycotic agent and natural antimycotic agent.The better combination that is combined as two-phenyl-(2-chloro-phenyl)-l-imidazole radicals methane (clotrimazole (Clotrimazol)) and tea tree ethereal oil.
The combination of the natural antimycotic agent of various differences.The better combination that is combined as Essential lavender oil, tea tree ethereal oil, Azadirachta Indica A. tree extract (Azadirachta indica) and ABC oil (the blue Resina Cupressi (Australian Blue Cypress Oil) in Australia) and thuyol.
Pyrrolidine 2 carboxylic acid (L-PROLINE) is selected among the group that following each thing forms other with one or more and nourishes combination with anabolic substance: aminoacid, vitamin and mineral.
Pyrrolidine 2 carboxylic acid (L-PROLINE) nourishes with the better of anabolic substance with one or more and is combined as and (S)-2,6-diaminocaproic acid (lysine), (R)-2-amino-3-hydro thiohydracrylic acid (cysteine (cystein)), gelatin, cis-2-(4-carboxybutyl)-3,4-urea groups Tetramethylene sulfide (biotin), (±) 2,4-dihydroxy-N-(3-hydroxypropyl)-3,3-acid dimethyl (panthenol), D (+)-2,4-dihydroxy-N-(3-hydroxypropyl)-3,3-acid dimethyl (pantothenylol) and inorganic or organic calcium, the combination of magnesium or zinc compound.
L-PROLINE is the anabolic substance that is particularly suitable for fingernail anabolism and fingernail maintenance.Composition part that the L-proline is only optionally selected for the fingernail skin care products at present is as the active component (EP-A-0 534 810) of the derivant that comprises sulfur-containing amino acid or sulfur-containing amino acid.
Above-mentioned substance is the respective name representative that represents with title in the bracket above hereinafter.
C as the supporting agent use
1-C
4-Arrcostab comprises methyl ester, ethyl ester, n-propyl, isopropyl ester, positive butyl ester, secondary butyl ester, isobutyl ester and the tert-butyl ester.The polybasic acid class: in malic acid, citric acid and the tartaric esters, C that its ester group comprises
1-C
4-alkyl can be identical or different.Can carry out esterification by all carboxylate radicals or part carboxylate radical such as above-mentioned polybasic acid class.Except malic acid and tartaric acid two-C
1-C
4Beyond-the Arrcostab, also can use corresponding malic acid and tartaric acid mono alkyl ester.The C of applicable citric acid
1-C
4-Arrcostab be corresponding single-, two-with the trialkyl ester.Better esters is ethyl ester.Other better esters is isopropyl esters.Better single compound is ethyl lactate.Other better single compound is (.+-.)-Diethyl malate and malic acid diisopropyl ester.
Topical products of the present invention is except one or more active ingredients and C as one or more lactic acid, malic acid, tartaric acid, citric acid, hendecanoic acid or the 9-undecylenic acid of supporting agent
1-C
4Outside-the Arrcostab, still can comprise adjuvant compatible on the physiology.Suitably adjuvant is for for example: terpenes or contain oil, alcohol, ketone, fatty acid ester, Polyethylene Glycol, surfactant, carbamide, antioxidant and the chelating agent of terpenes.
The terpenes that is fit to is acyclic, monocycle and bicyclic terpene and the oils that contains these terpenes.Be without the ring system terpene hydrocarbons without ring system terpenes example, as, for example: myrcene, acyclic terpene alcohol, as, for example: citronellol and geraniol, and without ring system terpene aldehyde and-ketone, as, for example: citral, α-ionone and β-ionone.The monocyclic terpene example is the monocyclic terpene hydro carbons, as, for example: α-terpin, γ-terpin and limonene, monocyclic terpene enol, as, for example: thymol, menthol, eucalyptole and carvacrol, and monocyclic terpene ketenes, as, for example: menthone and carvone.The bicyclic terpene example is the carane terpenoid, as, for example: carone, the pinane terpenoid, as, for example: australene and nopinene, and bornylane terpenoid, as, for example: Camphora and Borneolum Syntheticum.Particularly suitable terpenes is the monocyclic terpene enol, as, for example: thymol and menthol.The oils example that contains terpenes that is fit to is the cool oil of Oleum menthae, Xiao Beans, Oleum Pelargonii Graveolentis, Flos Rosae Rugosae quintessence oil, thuyol and hundred li oil.Particularly suitable oils is Oleum menthae, Essential lavender oil and hundred li oil.As above-mentioned, thuyol is particularly suitable for eliminating wart.
The alcohol that is fit to is to have the branch of 1 to 3 hydroxyl and 2 to 6 carbon atoms or the alcohol of branch not, and wherein hydroxyl can part or complete etherificate or esterification.Specially suitable alcohols is ethanol, 1-propanol, 2-propanol (isopropyl alcohol), 1,2-propylene glycol (propylene glycol), 2-phenylethanol (phenylethanol), n-butyl alcohol (butanols), glycol monomethyl methyl ether (methyl cellosolve), glycol monomethyl phenyl ether (phenyl phenol), 1,2,3-Glycerin (glycerol), ethyl acetate, butyl acetate, diacetine (diacetin) and glyceryl triacetate (glyceryl triacetate).
Suitable ketone example is acetone and methyl ethyl ketone (2-butanone).
Fatty acid ester is saturated and unsaturation, branch and the esters of 8 to 21 carbon atom fatty acids of branch not, and its pure composition comprises the branch of 1 to 6 carbon atom and branch's alcohols not.Particularly suitable fatty acid ester is tridecane carboxylic acid isopropyl esters, tetradecane carboxylic acid isopropyl esters (tetradeconic acid isopropyl ester), pentadecane carboxylate methyl ester and 9-octadecenic acid monoglyceride (glycerin mono-fatty acid ester (glycerin monooleate)).
Suitable Polyethylene Glycol is for for example: PEG400.
Suitable surfactant is for for example: nonionic interfacial activity composition.Specially suitable surfactant is the part fatty acid ester (Span) of sorbitan, the part fatty acid ester (Tween) of polyoxyethylene sorbitol acid anhydride, polyoxyethylated fatty acid ester (Myrj) and polyoxyethylated fatty alcohol ether (Brij).
Suitable antioxidant is for for example: butylated hydroxytoluene (BHT), butyl-4-methoxyphenol (BHA), tocopherol and ascorbic acid.
Suitable chelating agent is for for example: ethylenediaminetetraacetic acid (EDTA) and disodiumedetate (Na
2-ETDA).
Topical products for example can be according to the present invention: solution, tincture, emulsion, gel, ointment, cream and paste.Better local dispenser pattern is solution.
The present invention is relevant a kind of method for preparing topical products of the present invention also, it is characterized in that even mixed lactic ethyl ester and one or more adjuvant, then stir and add one or more active component to mixture, can optionally heat (the highest 80 ℃), continue to be stirred to and obtain till the homogeneous solution.Gained solution preferably is directly used in local dispenser.Yet this solution also can add compatible allotment adjuvant on other physiology, utilizes known dissolving, mixing and suspension method, converts another kind of local dispenser pattern to.
Topical products of the present invention is preferably and is the use of solution form.Better topical products comprises according to the present invention:
0.01 to one or more active ingredients of 20 % by weight,
One or more C of 1 to 99.99 % by weight lactic acid, malic acid, tartaric acid or citric acid
1-C
4-Arrcostab with
Compatible adjuvant on 0 to 98.99 one or more physiology of % by weight.
The present invention also about with topical products of the present invention in treatment, prevention, post processing or supportive treatment wart, disease of nail and first week disease, and the application in the fingernail maintenance.In addition, the present invention is still about with the application of product of the present invention in the fungal infection of hoof, pawl and the hook for the treatment of domestic animal and house pet.
The topical products that for example contains antimycotic agent is applicable to following disease:
-treatment, prevention and post processing be by dermophyte, yeast or mycete or the caused tinea unguium of mixed infection,
-treatment, prevention and post processing psoriasis, diabetes or AIDS patient's fingernail fungal infection,
The nail infection in-supportive treatment first week, as, for example: candida mycoderma (Candida paronychium).
For example contain antibiotic topical products and be applicable to for example following disease:
-supportive treatment and the pre-caused fingernail of bacteriological protection-infect with first week.
The topical products that for example contains antibacterial is applicable to for example following disease:
-treatment and the prevention caused fingernail of pathogen non-specific or that do not differentiate-infect with first week.
For example contain corticosteroid or be applicable to for example following disease by the topical products that corticosteroid and antimycotic agent, antibiotic or antibacterial are combined into:
The fingernail of-treatment, prevention, post processing or supportive treatment wart, fingernail-tinea or other inflammation-with first week disease.
Local medical product of the present invention is applicable to treat disease of nail and all diseases of first of wart, finger and toe, and can treat the disease of hoof, pawl and the hook of house pet and domestic animal.The dispenser frequency of medical product is according to the degree of disease and position and decide.Dispenser in common one day is for 1 to 3 time enough.Solution can be applied directly to the fingernail affected part, or hoof, pawl or hook, and if when needing, but dispenser is to the affected part surrounding skin.This therapy should continue about 2 weeks of dispenser after symptom is eliminated, to prevent recurrence.
The part that comprises one or more nourishings and anabolic substance according to the present invention is applicable to maintain fingernail with cosmetics, as, for example: the fingernail atrophy of toe and finger.The fingernail atrophy for example comprises: crisp, split and thin fingernail, and speckle or linear white macula appear.Said preparation is to be applied on the inaesthetic fingernail, and can be applied on the surrounding skin according to need.The dispenser frequency of preparation is according to the degree of atrophy and position and different.Usually, used 1-2 time in one day namely enough.
The advantage of topical products of the present invention is that it can make active component enter the fingernail affected part in several days, and plays a role at lactulum unguis and onychorrhiza place.Through the effect that faster begins and the osmosis of improvement thereof, the treatment of disease of nail was finished usually after about 2 to 3 months.Mode obviously can be improved patient's adaptability according to this, because it significantly shortens the required long-time treatment of other method.At the skin affected part, particularly on the perionychium skin position, its recovery from illness process and maintenance effect are very fast, because active component can fully and fast infiltrate in the skin.The fingernail maintenance was carried out one month usually.If keep healthy fingernail, but also the life-time service fingernail maintains product.
The specific embodiment
Following example is explanation the present invention:
Example 1:
Stir and add in carbamide to the 20 milliliter ethyl lactate, heating (about 50 ℃) dissolving in 100 ml flasks.Stir to add clotrimazole (Clotrimazol) to above-mentioned solution, then add ethyl lactate to 100 milliliter.Continue to be stirred to and form till the homogeneous solution.
Example 2:
Thuyol 2.0%
Ethyl lactate 98.0%
Example 3:
Thuyol 2.0%
Tea tree ethereal oil 1.0%
Lactic acid 2.0%
Ethyl lactate 95.0%
Example 4:
Thuyol 2.0%
Salicylic acid 2.0%
Ethyl malate 96.0%
Example 5:
Ciclopirox olamine 8.0%
(Ciclopiroxolamin)
Ethyl lactate 92.0%
Example 6:
Ethanol 5.0%
9-undecylenic acid 10.0%
Citric acid trimethyl ester 85.0%
Example 7:
Essential lavender oil 2.0%
9-undecylenic acid 10.0%
Ethyl lactate 88.0%
Example 8:
Stir and add in carbamide to the 20 milliliter ethyl lactate, heating (about 50 ℃) dissolving in 100 ml flasks.Stir to add clotrimazole (Clotrimazol) and tea tree ethereal oil to above-mentioned solution, then add ethyl lactate to 100 milliliter.Continue to be stirred to and form till the homogeneous solution.
Example 9:
Measure all substances and add in the beaker, be stirred to till the formation homogeneous solution.
Example 10:
Stir the mixture till form homogeneous solution.
Example 11:
Proline-solution 1.5%
L-PROLINE 1.5 grams
Propylene glycol 65.0 grams
Ethyl lactate 33.5 grams
Stir and add L-PROLINE to propylene glycol, and heating for dissolving.Add at last ethyl lactate, continue to be stirred to till the formation homogeneous solution.
Example 12:
L-PROLINE 2.0 grams
(.+-.)-Diethyl malate 93.0 grams
Isopropyl alcohol 5.0 grams
Stir and add L-PROLINE to (.+-.)-Diethyl malate, continue to be stirred to till the fully dissolving.
Example 13:
Show the present composition in the following table, it is to use each 50.0 gram according to hydroxy carboxylic acid-C of the present invention
1-C
4-Arrcostab is as supporting agent and each 1.0 gram active component.The method for making of compositions is that under room temperature or a little temperature lower (about 30 ℃ to 50 ℃) stirs and adds active component to hydroxycarboxylic acid esters.Different according to active component, stir after 1-5 hour, form immediately spendable solution.
| Active component | Hydroxycarboxylic acid esters |
| Clotrimazole (Clotrimazol) | Ethyl lactate |
| Isoconazole (Isoconazol) | Ethyl lactate |
| Ketoconazole (Ketoconazol) | Ethyl lactate |
| Itraconazole (Itraconazol) | Ethyl lactate |
| Clotrimazole (Clotrimazol) | Citric acid triethyl group ester |
| Isoconazole (Isoconazol) | Citric acid triethyl group ester |
| Ketoconazole (Ketoconazol) | Citric acid triethyl group ester |
| Itraconazole (Itraconazol) | Citric acid triethyl group ester |
| Clotrimazole (Clotrimazol) | The malic acid diisopropyl ester |
| Isoconazole (Isoconazol) | The malic acid diisopropyl ester |
| Ketoconazole (Ketoconazol) | The malic acid diisopropyl ester |
| Itraconazole (Itraconazol) | The malic acid diisopropyl ester |
Example 14:
Show other compositions of the present invention in the following table, it is to use each 88.0 gram according to hydroxy carboxylic acid-C of the present invention
1-C
4-Arrcostab is set the 12.0 gram active component combinations that extracts form as supporting agent and by 5 gram Essential lavender oil, 5 gram tea tree ethereal oils and 2 gram Azadirachta Indica A..Process for preparing composition is to stir to add active component to employed each hydroxycarboxylic acid esters under room temperature.The compositions of gained can be used.
Claims (19)
1. a topical products is for the manufacture of the application in the medicine for the treatment of wart, and wherein said topical products comprises
A) one or more active ingredients,
B) as the C of one or more lactic acid, malic acid, tartaric acid, citric acid, hendecanoic acid or the 9-undecylenic acid of supporting agent
1-C
4-Arrcostab, and
C) compatible adjuvant on the physiology that can optionally select.
2. application as claimed in claim 1 is characterized in that described supporting agent that described topical products comprises is selected from the ethyl ester of lactic acid, malic acid, tartaric acid, citric acid, hendecanoic acid or 9-undecylenic acid.
3. application as claimed in claim 1 is characterized in that described supporting agent that described topical products comprises is selected from the isopropyl esters of lactic acid, malic acid, tartaric acid, citric acid, hendecanoic acid or 9-undecylenic acid.
4. application as claimed in claim 1 or 2 is characterized in that the described supporting agent that described topical products comprises is ethyl lactate.
5. such as arbitrary described application in the claims 1 to 3, it is characterized in that the described supporting agent that described topical products comprises is hendecanoic acid methyl ester or methyl undecylenate.
6. such as arbitrary described application in the claims 1 to 3, it is characterized in that the described supporting agent that described topical products comprises is (.+-.)-Diethyl malate.
7. use as described in claim 1, it is characterized in that described topical products comprises one or more and is selected from following each thing and forms material among the group as described active component: synthesize or natural antimycotic agent, antibiotic, antibacterial, corticosteroid and nourishing and anabolic substance.
8. use as described in claim 1; it is characterized in that described topical products comprises one or more and is selected from following each thing and forms described antifungal active ingredient among the group: (±)-cis-2; 6-dimethyl-4-[2-methyl-3-(p-tertiary pentyl-phenyl) propyl group] morpholine (An Mofen (Amorolfin)); amphotericin (Amphotericin); 6-cyclohexyl-1-hydroxy-4-methyl-2 (1H)-pyridone (cyclopirox (Ciclopirox)); two-phenyl-(2-chlorphenyl)-1-imidazole radicals methane (clotrimazole (Clotrimazol)); l-[2-(2; the 4-Dichlorobenzene base)-2-(4-chlorophenylmethyl oxygen)-ethyl]-imidazoles (econazole (Econazol)); 2; 4-two fluoro-α; α-two (1H-l; 2; 4-triazole-l-ylmethyl) benzylated polyol (fluconazol (Fluconazol)); 5-flurocytosine (Flucytosin (Flucytosin)); 7-chloro-trimethoxy-methylspiro-[benzofuran-cyclohexene]-diketone (griseofulvin (Griseofulvin)); l-[2; 4-two chloro-β-(2; 6-dichloro-benzenes methyl oxygen)-phenethyl]-imidazoles (isoconazole (Isoconazol)); (±)-l-sec-butyl-4-{4-[4-(4-{[(2R*; 4S*)-2-(2; the 4-Dichlorobenzene base)-2-(1; 2; 4-triazol-1-yl methyl)-1; 3-dioxolanes-4-yl] methoxyl group } phenyl)-the 1-piperazinyl] phenyl }-4; 5-dihydro-1; 2; 4-triazole-5-ketone (itraconazole (Itraconazol)); ([2-(2 for (±) cis-l-acetyl group-4-{4-; the 4-Dichlorobenzene base)-2-(1H-imidazoles-l-ylmethyl)-l; 3-dioxolanes-4-yl] methoxyl group) phenyl } piperazine (ketoconazole (Ketoconazol)); l-[2; 4-two chloro-β-(2; 4-dichloro-benzenes methyl oxygen)-phenethyl]-imidazoles (miconazole (Miconazol)); (E)-N-cinnamyl-N-methyl isophthalic acid-naphthyl methyl amine (naftifine (Naftifin)); nystatin (Nystatin); (E)-(6; 6-dimethyl-2-heptene-4-alkynyl)-N-methyl isophthalic acid-naphthyl methyl amine (terbinafine (Terbinafin)); 1-[2-{ (2-chloro-3-thienyl) methoxyl group }-2-(2; the 4-Dichlorobenzene base) ethyl]-1H-imidazoles (tioconazole (Tioconazol)); O-2-naphthyl-N-methyl-N-(3-tolyl)-thiocarbamate (tolnaftate (Tolnaftat)); α-(2; the 4-difluorophenyl)-5-fluoro-beta-methyl-α-(1H-1; 2,4-triazol-1-yl methyl)-4-pyrimidine ethanol (voriconazole (Voriconazol)).
9. use as described in claim 1, it is characterized in that described topical products comprises one or more and is selected from: described antibacterium or described antifungal active component in tea tree ethereal oil, Essential lavender oil, thuyol, Azadirachta Indica A. tree extract and the ABC oil.
10. use as described in claim 1, it is characterized in that comprising in the described topical products one or more and be selected from described antibacterium or described antifungal active component in thuyol and the ABC oil.
11. use as described in claim 1; it is characterized in that described topical products comprises one or more and is selected from following each thing and forms described antibiotic activity composition among the group: alpha-amido-4-hydroxy benzenes heterocyclic group containing (amoxicillin (Amoxicillin)); D-(-)-alpha-amido benzyl penicillin (ampicillin (Ampicillin)); 3; 3-dimethyl-7-oxo-6-phenylacetyl amido-4-thia-1-azabicyclo-[3.2.0]-heptane-2-carboxylic acid (benzylpcnicillin); benzylpcnicillin-benzyl star; 3-chloro-7-D (the 2-phenylglycine is amino)-cephalo acid (cefaclor (Cefaclor)); 7 β-[D-2-amino-(4-hydroxyl-phenyl)-acetyl-amino]-3-methyl-cephalo acid (cefadroxil (Cefadroxil)); aminophenyl-acetylaminohydroxyphenylarsonic acid methyl-cephalo acid (cefalexin (Cefalexin)); D (-)-p-2-dichloro acetamino-1-(4-nitrobenzophenone)-1; ammediol (chloromycetin (Chloramphenicol); 1-cyclopropyl-6-fluoro-1; 4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinoline carboxylic acid (ciprofloxacin (Ciprofloxacin)); (Z)-(2R; 5R)-3-(2-hydroxy ethylene)-7-oxo-4-oxa--1-azabicyclo [3.2.0] heptane-2-carboxylic acid (clavulanic acid (Clavulanic acid)); 7-chloro-7-deoxidation-lincomycin (clindamycin (Clindamycin)); 6-deoxidation-5-hydroxyl tetracycline (doxycycline (Doxycyclin)); 1-ethyl-6-fluoro-1; 4-dihydro-4-oxo-7-(l-piperazinyl)-l; 8-naphthyridines-3-carboxylic acid (Yi Nuoshaxin (Enoxacin)); erythromycin; 3-(2-chloro-6-fluorophenyl)-5-methyl-4-isoxazolyl-penicillin (flucloxacillin (Flucloxacillin)); kanamycin (Kanamycin); lincomycin (Lincomycin); 7-dimethylamino-6-deoxidation-6-declomycin (minocycline (Minocyc-lin)); 6-(2-ethyoxyl-1-naphthoyl amido)-penicillin (nafcillin (Nafcilin)); l-ethyl-l; 4-dihydro-7-methyl-4-oxo-l; 8-naphthyridines-3-carboxylic acid (nalidixic acid (Nalidxic acid)); neomycin (Neomycin); l-ethyl-6-fluoro-l; 4-dihydro-4-oxo-7-(l-piperazinyl)-3-quinoline carboxylic acid (norfloxacin (Norfloxacin)); (±)-9-fluoro-2; 3-dihydro-3-methyl isophthalic acid 0-(4-methyl isophthalic acid-piperazinyl)-7-oxo-7H-pyrido [l; 2; 3-de] [l; 4] benzoxazine-6-carboxylic acid (ofloxacin (Ofloxacin)); 6-(5-methyl-3-phenyl-4-isoxazole carboxamide groups) penicillanic acid (toluene isoxazolyl penicillin (Oxacillin)); 6-phenoxy group acetyl-amino-penicillanic acid (phenoxymethyl penicillin) and 4-dimethyl amido-octahydro-penta hydroxy group-1,11-dioxo-6-methyl-naphthonaphthalene-2-urea (tetracycline).
12. use as described in claim 1, it is characterized in that described topical products comprises one or more and is selected from following each thing and forms described Antibacterial Constituents among the group: alkylbenzene methyl dimethoxy ammonium chloride (benzene is pricked chlorine ammonia), N-benzyl-N, N-dimethyl-2-{2-[p-(1,1,3, the 3-tetramethyl butyl)-phenoxy group]-ethyoxyl }-ethyl ammonium hydroxide (benzethonium chloride), cetyl trimethylammonium hydroxide (cetrimonium bromide (Cetrimonium bromid)), 1,1 '-hexa-methylene-two-[5-(rubigan)-biguanide] (hibitane (Chlorhexidin)), N
1, N
1-decamethylene-two-(4-amino methyl quinaldine hydroxide) (dequaline chloride (Dequalinium chlorid)), N-(4-chlorphenyl)-N '-(3, the 4-Dichlorobenzene base) urea (neko (Triclocarbane)), 5-chloro-2-(2,4-dichlorophenoxy) phenol (triclosan (Triclosan)).
13. use as described in claim 1; it is characterized in that described topical products comprises one or more and is selected from following each thing and forms described corticosteroid active component among the group: 9 α-chloro-16 Beta-methyl hydrogenation Bo Nisong (beclometasone (Beclomethason)); 9-fluoro-l1 β; 17; 21-trihydroxy-16 Beta-methyl-1; 4-pregnant diene-3; 20-diketone (betamethasone (Betamethason)); 21-chloro-9-fluoro-11 β; 17-dihydroxy-16 Beta-methyl-1; 4-pregnant diene-3; 20-diketone (Clobetasol (Clobetasol)); 17; 21-dihydroxy-pregnant-4-alkene-3; 11; 20-triketone (cortisone (Cortisone)); 11 β; 16 α; 17 α; 21-tetrahydroxy-1; 4-pregnant diene-3; 20-diketone-16; 17-acetone acetal (desonide (Desonid)); 9-fluoro-l1 β-17; pregnant steroid-the l of 21-trihydroxy-16 Alpha-Methyl; 4-diene-3; 20-diketone (dexamethasone (Dexamethason)); 9 α; 11 β-two chloro-, 6 α-fluoro-21-hydroxy-16 alpha-; 17 α-(isopropylidene dioxy)-pregnant steroid-1; 4-diene-3; 20-diketone (flucloronide (Flucloronid)); 6 α; 9 α-two fluoro-, 16 α; 17 α-isopropylidene dioxy-corticosterone (fluocinonide (Fluocinolonacetonid)); 6 α; 9 α-two fluoro-, 16 α; 17 α-isopropylidene dioxy-corticosterone-acetate (fluocinonide (Fluocinonid)); 6 α-fluoro-11 β; 21-dihydroxy-6 α; 17-isopropylidene dioxy-4-pregnene-3; 20-diketone (flurandrenolide (Fludroxycortid)); 3-(2-chloroethoxy)-9 α-fluoro-6-formoxyl-11 β; 21-dihydroxy-16 α; 17 α-isopropylidene dioxy pregnant-3; 5-diene-20-ketone (formocortal (Formocortal)); 21-chloro-9 α-fluoro-11 beta-hydroxies-16 α; 17 α-isopropylidene dioxy-4-pregnene-3; 20-diketone (breathing out western naphthalene moral (Halcinonid)); 17 Alpha-hydroxy corticosterones (hydrocortisone (Hydrocortison)); 11 β; 17; 21-trihydroxy-6 Alpha-Methyl-1; 4-pregnant diene-3; 20-diketone (medrat (Methylprednisolon)); 11 β; 17; 21-trihydroxy-pregnant-1; 4-diene-3; 20-diketone (meticortelone (Prednisolon)); 17 α; 21-dihydroxy-pregnant-1; 4-diene-3; 11; 20-triketone (prednisone (Prednison)); 9-fluoro-16 Alpha-hydroxy andrographolides (acetone Triamcinolone (Triamcinolon)); acetone Triamcinolone-16 α, 17 α-acetone solvate (triamcinolone acetonide (Triamcinolonacetonid)).
14. use as described in claim 1, it is characterized in that described topical products comprises nourishing and anabolic substance L-PROLINE.
15. use as described in claim 1, it is characterized in that described topical products comprises described L-PROLINE and one or more and is selected from aminoacid, vitamin and mineral and forms nourishing among the group and the combination of anabolic substance.
16. use as described in claim 1, it is characterized in that described topical products comprises described L-PROLINE and one or more are selected from: lysine, cysteine, gelatin, biotin, panthenol, pantothenylol and the nourishing of inorganic or organic calcium, magnesium or zinc compound and the combination of anabolic substance.
17. use as described in claim 1, it is characterized in that described topical products comprises one or more and is selected from following each thing and forms adjuvant among the group: terpenes or contain oil, alcohol, ketone, fatty acid ester, Polyethylene Glycol, surfactant, carbamide, antioxidant and the chelating agent of terpenes.
18. use as described in claim 1, it is characterized in that described topical products comprises one or more active ingredients of 0.01 to 20 % by weight, the C of the lactic acid of 1 to 99.99 % by weight, malic acid, tartaric acid, citric acid, hendecanoic acid or 9-undecylenic acid
1-C
4-Arrcostab is with 0 to 98.99 % by weight adjuvant.
19. the described topical products in the application claimed in claim 1 is used for the treatment of application in the medicine of hoof, pawl and hook fungal infection of house pet and domestic animal in manufacturing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013102038263A CN103357015A (en) | 2005-09-29 | 2005-09-29 | Local preparation for removing verruca and nail diseases and taking care of nails |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013102038263A CN103357015A (en) | 2005-09-29 | 2005-09-29 | Local preparation for removing verruca and nail diseases and taking care of nails |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200510105663 Division CN1939539A (en) | 2005-09-29 | 2005-09-29 | Local prescription for wart, nail-disease treatment and nail care |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103357015A true CN103357015A (en) | 2013-10-23 |
Family
ID=49359808
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2013102038263A Pending CN103357015A (en) | 2005-09-29 | 2005-09-29 | Local preparation for removing verruca and nail diseases and taking care of nails |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103357015A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018509464A (en) * | 2015-01-23 | 2018-04-05 | バイオシディウム バイオファーマスーティカルズ インコーポレイテッド | Antibacterial composition |
| CN110038010A (en) * | 2019-04-28 | 2019-07-23 | 瑞雅科医药(北京)有限公司 | A kind of bitter taste detests preparation and preparation method thereof and bite preventing pen |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6143793A (en) * | 1991-03-08 | 2000-11-07 | Novartis Ag | Use of hydrophilic penetration agents in dermatological compositions for the treatment of onychomycoses, and corresponding compositions |
| US6740326B1 (en) * | 1998-09-10 | 2004-05-25 | Bioequal Ag | Topical nail care compositions |
| CN1631369A (en) * | 2003-12-23 | 2005-06-29 | 高克 | Cream for treating skin disease |
-
2005
- 2005-09-29 CN CN2013102038263A patent/CN103357015A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6143793A (en) * | 1991-03-08 | 2000-11-07 | Novartis Ag | Use of hydrophilic penetration agents in dermatological compositions for the treatment of onychomycoses, and corresponding compositions |
| US6740326B1 (en) * | 1998-09-10 | 2004-05-25 | Bioequal Ag | Topical nail care compositions |
| CN1631369A (en) * | 2003-12-23 | 2005-06-29 | 高克 | Cream for treating skin disease |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018509464A (en) * | 2015-01-23 | 2018-04-05 | バイオシディウム バイオファーマスーティカルズ インコーポレイテッド | Antibacterial composition |
| US10716305B2 (en) | 2015-01-23 | 2020-07-21 | Biocidium Biopharmaceuticals Inc. | Anti-bacterial compositions |
| US11363814B2 (en) | 2015-01-23 | 2022-06-21 | Biocidium Ip Holdco, Co. | Anti-bacterial compositions |
| CN110038010A (en) * | 2019-04-28 | 2019-07-23 | 瑞雅科医药(北京)有限公司 | A kind of bitter taste detests preparation and preparation method thereof and bite preventing pen |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5170486B2 (en) | Topically applicable product | |
| US10105444B2 (en) | Compositions and methods for treating diseases of the nail | |
| JP4828563B2 (en) | External preparation for athlete's foot treatment | |
| KR20080080355A (en) | Pharmaceutical composition for application to nail | |
| JP2007153910A (en) | Antimycotic nail polish composition | |
| JP2009510087A (en) | Stable ascorbic acid composition | |
| JP2004352688A (en) | Antiseptic agent | |
| CN103357015A (en) | Local preparation for removing verruca and nail diseases and taking care of nails | |
| CN1939539A (en) | Local prescription for wart, nail-disease treatment and nail care | |
| KR20210065968A (en) | Iron Chelating Compounds for Treating Aesthetic Skin Conditions | |
| AU2005203232B2 (en) | Topical formulations for the treatment of papillary tubercles, nail diseases and nail care | |
| ES2309546T3 (en) | PHARMACEUTICAL AND COSMETIC FORMULATIONS FOR THE TREATMENT OF NAILS. | |
| BE1018742A3 (en) | COMPOSITION FOR TREATMENT OF NAIL MEL DISEASES AND USE THEREOF. | |
| TWI520729B (en) | Topische formulierungen fuer anwendung bei warzen, nagelerkrankungen und zur nagelpflege | |
| KR20060104011A (en) | Topical formulation to be applied to wart removal, nail-disease treatment and nail care | |
| KR20140048908A (en) | Topical formulation to be applied to wart removal, nail-disease treatment and nail care | |
| TW201622710A (en) | Topical formulation for the treatment of papillary tubercles, nail diseases and nail care | |
| RU2093141C1 (en) | Agent for feet care | |
| MXPA05005429A (en) | Topical formulations for treating warts, finger nail diseases, and nail care | |
| KR20130001197A (en) | Topical formulation to be applied to wart removal, nail-disease treatment and nail care | |
| CN112957359A (en) | Nail polish composition containing ciclopirox | |
| WO2018116190A1 (en) | Topical sprayable compositions of ketorolac tromethamine | |
| MXPA06003354A (en) | Pharmaceutical and cosmetic formulations for treating fingernails |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1189488 Country of ref document: HK |
|
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20131023 |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1189488 Country of ref document: HK |